About Vectus Biosystems Limited

Leadership Team

Dr Karen Duggan
Executive Director and Chief Executive Officer

Dr Karen Duggan is a founder of Vectus and has served on its Board since 2005. She was formally director of the Hypertension Service – South Western Sydney Area Health Service (SWSAHS), and is the immediate past chair of the National Blood Pressure and Vascular Disease Advisory Committee. She was also a member of the Cardiovascular Health Advisory Committee of the National Heart Foundation of Australia and the Post-Acute Stroke Guidelines Advisory Committee of the Australian Government Department of Health and Aging. She remains a member of the Cardiovascular Clinical Expert Reference Group of the NSW Department of Health. In her role as Director of the Hypertension Service SWSAHS she was responsible for managing a multidisciplinary team (medical, nursing, laboratory and administrative staff), as well as developing and implementing new and innovative strategies in patient care within SWSAHS. The Hypertension Service participated in a number of clinical trials of both new therapeutics as well as evaluation of new diagnostic devices.

Mr Maurie Stang
Non-Executive Deputy Chairman

Mr Maurie Stang has a 30-year track record of building successful companies in the Australasian healthcare market and is recognised as one of its most respected business executives. Mr M Stang has significant experience and an extensive network within the life-sciences, pharmaceutical and finance sectors, both in Australia and internationally. He is a Principal of GryphonCapital, an independent investment house that facilitates the financing and development of emerging healthcare related entities. Mr M Stang is Chairman of Nanosonics Limited (ASX:NAN) and Aeris Environmental Ltd (ASX:AEI), both ASX-listed public companies. He is also a Founder and Director of Henry Schein Halas, a joint venture with the NASDAQ listed Henry Schein, Inc., the leading wholesale supplier of dental products in Australasia. Mr M Stang is a Director of Novapharm Research (Australia) Pty Ltd and of Regional Health Care Group (a diversified healthcare product supplier, with successful businesses across a range of medical, pharmaceutical, consumer healthcare, and research and development sectors).

Mr Peter Bush
Non-Executive Director

Mr Peter Bush (BCom, CA) previously acted as the Chief Financial Officer and Company Secretary of Vectus and of Accugen. He is also the Chief Executive Officer of Aeris Environmental Ltd, and an Executive Director and the Chief Financial Officer of The Regional Health Care Group and GryphonCapital. Mr Bush began his career working for five years at BDO, a global accounting and consulting firm, and has since spent several years working in industry.

Dr Ronald Shnier
Non-Executive Director

Dr Ronald Shnier completed a radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles (UCLA) in 1991. Dr Shnier was a consultant specialist at RPAH between 1990 and 1993. He started one of Australia’s first Private MRI practices in 1991 before becoming General Manager of Mayne’s Diagnostic Imaging in 2007 and was its National Director for many years. Dr Shnier has served on several international MRI advisory boards. He has a strong involvement in clinical research, and has lectured both in Australia and overseas.

Dr Susan Pond
Non-Executive Director

Dr Pond AM (MB, BS, MD, DSc, FTSE, FRACP) has a strong scientific and commercial background, having held executive positions in the biotechnology and pharmaceutical industry for 13 years, including as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003 to 2009). She has also held Board positions such as: Non‑Executive Director and Chairman of AusBiotech Limited (2007-2008); Director of the Australian Nuclear Science and Technology Organisation (2010 to 2014); Board member of Innovation Australia (2012 -2015) and Commercialisation Australia (2012 to 2014); and Vice President of the Australian Academy of Technological Sciences and Engineering Limited (2010 to 2015). Dr Pond is a Fellow of the Australian Institute of Company Directors, and the Australian Academy of Health and Medical Sciences. She obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology, and has held academic appointments at the University of California in San Francisco and the University of Queensland. Dr Pond has been a Director of Biotron Limited (ASX:BIT) since 7 March 2012. In February 2017 she took up the appointment of Director of the Australian Institute for Nanoscale Science & Technology at the University of Sydney.

Mr Robert Waring
Company Secretary Mr Robert Waring (BEc, CA, FCIS, FFin, FAICD) has over 40 years’ worth of experience in financial and corporate roles, including over 25 years in Company Secretarial roles for ASX-listed companies, and over 20 years as a Director of ASX-listed companies. Mr Waring has significant company secretarial experience for both listed and unlisted companies, and is currently serving as Company Secretary for ASX-listed companies Aeris Environmental Ltd (ASX:AEI), Xref Limited (ASX:XF1) and Cobalt Blue Holdings Limited (ASX:COB). He is a Director of Oakhill Hamilton Pty Ltd, which provides secretarial and corporate advisory services to a range of listed and unlisted companies.  
×